Renal

Dr Joshua Rein Discusses the Next Steps of Cannabis Treatment for Kidney Disease

October 31st 2020, 1:00pm

Video

The federal illegality and Schedule I listing of cannabis significantly impair our ability to conduct any kind of prospective clinical research, said Joshua L Rein, DO, FASN, a nephrologist at Mt. Sinai Hospital in New York City.

Research Highlights Impact of SDOH on Veterans With CKD

October 30th 2020, 4:00pm

Article

A pair of abstracts presented at Kidney Week 2020 underscore the relationship between social determinants of health (SDOH) and chronic kidney disease (CKD) in military populations and the challenges of tracking these factors.

Empagliflozin Cuts Risk of CV, Kidney Events in Heart Failure Regardless of CKD Status

October 24th 2020, 4:15pm

Article

New results from EMPEROR-Reduced presented at Kidney Week 2020.

UW Medical Students Force Change to Key Kidney Measure to End Disparity

October 16th 2020, 1:15pm

Article

Prompted by students, the medical school overturned a longstanding diagnostic protocol that was not well-founded in evidence.

Dialysis Is on the Ballot Again in California

October 14th 2020, 12:45pm

Article

For-profit dialysis centers are spending heavily to defeat the measure.

Surgeon General Issues Call to Action on Hypertension

October 10th 2020, 12:00pm

Article

The recent focus on disparities in health care comes through in the call to action.

Dapagliflozin Gets Breakthrough Therapy Designation for CKD

October 2nd 2020, 7:19pm

Article

The FDA action follows presentation of results in August during the European Society of Cardiology 2020 Virtual Congress.

New VERTIS-CV Analysis Finds Renal Benefits for Ertugliflozin on Par With Other SGLT2s

September 29th 2020, 12:45pm

Article

A new analysis shows that ertugliflozin matched renal results seen in trials for a pair of rival sodium glucose cotransporter 2 (SGLT2) inhibitors.

Combo for Metastatic Kidney Cancer Cuts Death Risk 40%

September 21st 2020, 4:42pm

Article

Nivolumab, a checkpoint inhibitor, and cabozantinib, a targeted therapy, produced dramatic results when used in combination for patients with newly diagnosed advanced kidney cancer.

Reducing Urinary Protein Improves Survival for Patients With Rare Kidney Disease

September 20th 2020, 1:00pm

Article

Researchers suggest that clinical trial design could be shaped by measuring reductions in urinary protein.